2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries

October 8 | 2019
2cureX AB (“2cureX”, NASDAQ: 2CUREX) today announces that the company has established a commercial agreement with one of the largest private cancer hospitals in the Nordic countries to evaluate IndiTreat’s usefulness in clinical practise.

2cureX launches the IndiTreat® test in the European market in 2020. In preparation, 2cureX plans to establish commercial agreements with four innovative cancer centers in selected European markets by the end of 2019. For 2cureX, such collaborations are valuable opportunities to gain experience with the IndiTreat® test in daily clinical practice.

IndiTreat® provides a novel functional test that supports the existing diagnostic processes for clinicians in order to individualize cancer treatment. The technology identifies the drug treatment to which the individual patient is sensitive and just as important, to which treatment the patient is resistant. Agreements obtained with innovative cancer centers during the launch preparation phase provide valuable information about the practical implementation of IndiTreat® in the existing cancer care workflow.

“Working together with one of the largest private cancer hospitals in the Nordic countries is an important milestone for 2cureX’s path towards the IndiTreat® launch in 2020”, says Ole Thastrup, Chief Executive Officer and he continues; “To meet the requests from the commercial partners, we have scaled up our production capacity, and strengthened the commercial team. I therefore feel that 2cureX is well prepared for the commercialisation of IndiTreat®”.

To strengthen the commercialization, 2cureX is running eight clinical programs, which continuously provide data that will improve the test´s ability to identify the most effective medical treatment for each cancer patient.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 8th, 2019.

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.

IndiTreat® is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is presently being introduced into the European market through an Early Access Program. 

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).